Total Valuation
Shanghai Pharmaceuticals Holding Co has a market cap or net worth of $8.23B. The enterprise value is $91.14B.
Market Cap$8.23B
Enterprise Value$91.14B
Share Statistics
Shanghai Pharmaceuticals Holding Co has 919,072,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding919,072,700
Owned by Insiders―
Owned by Institutions<0.01%
Financial Efficiency
Shanghai Pharmaceuticals Holding Co’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 4.97%.
Return on Equity (ROE)0.08
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)4.97%
Return on Capital Employed (ROCE)0.10
Revenue Per Employee5.72M
Profits Per Employee140.58K
Employee Count49,608
Asset Turnover1.22
Inventory Turnover5.58
Valuation Ratios
The current PE Ratio of Shanghai Pharmaceuticals Holding Co is 10.7. Shanghai Pharmaceuticals Holding Co’s PEG ratio is 0.26.
PE Ratio10.7
PS Ratio0.13
PB Ratio0.50
Price to Fair Value0.50
Price to FCF9.90
Price to Operating Cash Flow8.27
PEG Ratio0.26
Income Statement
In the last 12 months, Shanghai Pharmaceuticals Holding Co had revenue of 283.58B and earned 5.72B in profits. Earnings per share was 1.54.
Revenue283.58B
Gross Profit30.42B
Operating Income9.94B
Pretax Income9.82B
Net Income5.72B
EBITDA14.37B
Earnings Per Share (EPS)1.54
Cash Flow
In the last 12 months, operating cash flow was 7.58B and capital expenditures -2.29B, giving a free cash flow of 5.29B billion.
Operating Cash Flow7.58B
Free Cash Flow5.29B
Free Cash Flow per Share5.76
Dividends & Yields
Shanghai Pharmaceuticals Holding Co pays an annual dividend of $0.052, resulting in a dividend yield of 3.35%
Dividend Per Share$0.052
Dividend Yield3.35%
Payout Ratio18.75%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.26
52-Week Price Change0.40%
50-Day Moving Average1.50
200-Day Moving Average1.51
Relative Strength Index (RSI)53.86
Average Volume (3m)0.00
Important Dates
Shanghai Pharmaceuticals Holding Co upcoming earnings date is Aug 28, 2026, TBA (Confirmed).
Last Earnings DateApr 29, 2026
Next Earnings DateAug 28, 2026
Ex-Dividend Date―
Financial Position
Shanghai Pharmaceuticals Holding Co as a current ratio of 1.33, with Debt / Equity ratio of 81.00%
Current Ratio1.33
Quick Ratio1.00
Debt to Market Cap1.27
Net Debt to EBITDA1.17
Interest Coverage Ratio5.90
Taxes
In the past 12 months, Shanghai Pharmaceuticals Holding Co has paid 2.85B in taxes.
Income Tax2.85B
Effective Tax Rate0.29
Enterprise Valuation
Shanghai Pharmaceuticals Holding Co EV to EBITDA ratio is 3.80, with an EV/FCF ratio of 14.28.
EV to Sales0.19
EV to EBITDA3.80
EV to Free Cash Flow14.28
EV to Operating Cash Flow8.88
Balance Sheet
Shanghai Pharmaceuticals Holding Co has $40.98B in cash and marketable securities with $62.41B in debt, giving a net cash position of -$21.43B billion.
Cash & Marketable Securities$40.98B
Total Debt$62.41B
Net Cash-$21.43B
Net Cash Per Share-$23.31
Tangible Book Value Per Share$18.41
Margins
Gross margin is 10.83%, with operating margin of 3.51%, and net profit margin of 2.02%.
Gross Margin10.83%
Operating Margin3.51%
Pretax Margin3.46%
Net Profit Margin2.02%
EBITDA Margin5.07%
EBIT Margin4.06%
Analyst Forecast
The average price target for Shanghai Pharmaceuticals Holding Co is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast6.29%
EPS Growth Forecast35.39%